-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HCV-IN-39
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/2087916-31-0.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 2087916-31-0 |
| Description | HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC50 values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons. |
Product Information
| Synonyms | HCV-IN-39|CHEMBL4640800|SCHEMBL18549079|HY-147763|CS-0527307 |
| Molecular Weight | 610.78 |
| Molecular Formula | C21H26BrClN3O9P |
| Canonical SMILES | CCOC(=O)C(C)(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(Cl)Br)O)OC3=CC=CC=C3 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 932 |
| Exact Mass | 609.02786 |
| Target | EC50: 0.644 μM (GT1a), 0.952 μM (GT1b), 0.154 μM (GT1b CES1) |
| XLogP3-AA | 1.5 |